Targets › PDE6H
3 programs from 3 companies in 3 trials: 2 Phase 2, 1 Phase 4; Genitourinary, Cardiovascular, Neurology; next expected readout Dec 2026.
Inhibitory gamma subunit of the cone-specific cGMP phosphodiesterase (PDE6) complex which hydrolyzes 3',5'-cyclic GMP in the phototransduction cascade (By similarity). The PDE6 holoenzyme consists of two catalytic alpha subunits (PDE6C) and two inhibitory gamma subunits (PDE6H) (By similarity). (UniProt, Q13956)
Open in Phaseline: the race on PDE6H, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Vastra Gotaland Region | Dipyridamole Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor | SLC29A1, PDE5A, PDE4A, PDE3A, PDE6H | Phase 4 | Takotsubo Syndrome | Dec 2028 |
| Yunfeng Xia | Dipyridamole Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor | SLC29A1, PDE5A, PDE4A, PDE3A, PDE6H | Phase 2 | Restless Leg Syndrome Due to Uraemia | Dec 2026 |
| Stanford University | Dipyridamole Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor | SLC29A1, PDE5A, PDE4A, PDE3A, PDE6H | Phase 2 | Hypophosphatemia | May 2027 |
Hypophosphatemia (1) Takotsubo Syndrome (1) Restless Leg Syndrome Due to Uraemia (1)
small molecule (3)
Stanford University (1) Vastra Gotaland Region (1) Yunfeng Xia (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.